Efficacy of contrast-enhanced FDG PET/CT in patients awaiting liver transplantation with rising alpha-fetoprotein after bridge therapy of hepatocellular carcinoma

• Published in: European radiology 2018-12, Vol.28 (12), p.5356-5367
• Main Authors: Refaat, Rania, Basha, Mohammad Abd Alkhalik, Hassan, Mohammed Sobhi, Hussein, Rasha S., El Sammak, Ahmed A., El Sammak, Dena Abd El Aziz, Radwan, Mohamed Hesham Saleh, Awad, Nahla M., Saad El-Din, Somaia A., Elkholy, Engi, Ibrahim, Dina R. D., Saleh, Shereen A., Montasser, Iman F., Said, Hany
• Format: Article
• Language: English
• Subjects: Accuracy; Adult; Aged; alpha-Fetoproteins - metabolism; Biomarkers, Tumor - blood; Carcinoma, Hepatocellular - blood; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - therapy; Computed tomography; Diagnostic Radiology; Diagnostic systems; Female; Fluorine; Fluorine isotopes; Fluorodeoxyglucose F18 - pharmacology; Follow-Up Studies; Glucose; Hepatocellular carcinoma; Histopathology; Humans; Image enhancement; Imaging; Internal Medicine; Interventional Radiology; Lesions; Liver; Liver cancer; Liver Neoplasms - blood; Liver Neoplasms - diagnosis; Liver Neoplasms - therapy; Liver Transplantation; Liver transplants; Male; Medicine; Medicine & Public Health; Metastases; Middle Aged; Neuroradiology; Nuclear Medicine; Patients; Positron emission; Positron emission tomography; Positron Emission Tomography Computed Tomography - methods; Prospective Studies; Radiology; Radiopharmaceuticals - pharmacology; Therapy; Tomography; Transplantation; Tumors; Ultrasound; Waiting Lists; α-Fetoprotein
• ISSN: 0938-7994; 1432-1084
• DOI: 10.1007/s00330-018-5425-z

Objective To assess the diagnostic accuracy and illustrate positive findings of contrast-enhanced fluorine-18 fluoro-D-glucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) image in patients awaiting liver transplantation (LT) with rising alpha-fetoprotein (AFP) after bridge therapy of hepatocellular carcinoma (HCC). Materials and methods This prospective study included 100 patients who were waiting for LT and who previously underwent locoregional therapy (LRT) of HCC. These patients had rising AFP levels on a routine follow-up examination awaiting LT. All patients underwent a contrast-enhanced 18 F-FDG PET/CT examination. We calculated for each patient the maximum standardised uptake value (SUVmax) of the tumour and the ratio of the tumoral SUVmax to the normal-liver SUVmax. The diagnostic accuracy and positive contrast-enhanced findings of 18 F-FDG PET/CT were established by histopathology and clinical and imaging follow-up as the reference standards. Results Contrast-enhanced 18 F-FDG PET/CT detected tumour relapse in 78 patients (13 patients had intrahepatic lesions, 10 patients had extrahepatic metastases and 55 patients with combined lesions). The sensitivity, specificity and accuracy values of contrast-enhanced 18 F-FDG PET/CT examination in the detection of HCC recurrence were 92.8%, 94.1% and 93%, respectively. A significant correlation was found between the AFP level and SUVmax ratio ( r = 0.2283; p = 0.0224). The best threshold for 18 F-FDG PET positivity was >1.21. Conclusion Contrast-enhanced 18 F-FDG PET/CT is a valuable tool for the detection of intrahepatic HCC recurrence or extrahepatic metastasis following rising AFP levels after LRT of HCC, and should be incorporated during routine workup awaiting LT. Key Points • 18 F-FDG PET/CT is a valuable tool for the detection of HCC recurrence • 18 F-FDG PET/CT should be incorporated during routine workup awaiting liver transplantation • Significant correlation was found between AFP level and SUVmax ratio • The best threshold for 18 F-FDG PET positivity was >1.21 • The ideal cut-off value for AFP was >202